Amyloid β-Peptide (1-42)-induced oxidative stress in alzheimer disease: Importance in disease pathogenesis and progression

Antioxidants and Redox Signaling

Volumn 19, Issue 8, 2013, Pages 823-835

  Butterfield, D Allan ^a,b   Swomley, Aaron M ^a,b   Sultana, Rukhsana ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BRAIN PROTEIN; FREE RADICAL; GAMMA SECRETASE; LIPID; METHIONINE; METHIONINE SULFOXIDE; METHIONINE SULFOXIDE REDUCTASE; PEPTIDYLPROLYL ISOMERASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE COURSE; DOWN SYNDROME; ENZYME MECHANISM; EPISODIC MEMORY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIPID BILAYER; LIPID PEROXIDATION; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; NITROSATIVE STRESS; OLIGOMERIZATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN MODIFICATION; PROTEOMICS; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; FREE RADICALS; HUMANS; METHIONINE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, QUATERNARY;

EID: 84877072330     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5027     Document Type: Review

References (174)

1. Aaronson RM, Graven KK, Tucci M, McDonald RJ, and Farber HW. Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270: 27752-27757, 1995.
2. Abe T, Tohgi H, Isobe C, Murata T, and Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res 70: 447-450, 2002.
3. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, and Markesbery WR. The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J Mol Neurosci 11: 151-164, 1998.
4. Aluise CD, Robinson RAS, Cai JA, Pierce WM, Markesbery WR, and Butterfield DA. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J Alzheimers Dis 23: 257-269, 2011.
5. Balastik M, Lim J, Pastorino L, and Lu KP. Pin1 in Alzheimer's disease: multiple substrates one regulatory mechanism? Biochim Biophys Acta 1772: 422-429, 2007
6. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, Perluigi M, Mancuso C, and Butterfield DA. Biliverdin reductase-a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta 1812: 480-487, 2011.
7. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, and Butterfield DA. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment. J Alzheimers Dis 25: 623-633, 2011.
8. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, and Butterfield DA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52: 2292-2301, 2012.
9. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, and Butterfield DA. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 1044: 206-215, 2005.
10. Boyd-Kimball D, Mohmmad Abdul H, Reed T, Sultana R, and Butterfield DA. Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Chem Res Toxicol 17: 1743-1749, 2004.
11. Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce WM, Jr., Klein JB, Ferguson J, Link CD, and Butterfield DA. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiol Aging 27: 1239-1249, 2006.
12. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15: 223-240, 2008.
13. Butterfield DA. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. Chem Res Toxicol 10: 495-506, 1997.
14. Butterfield DA, Abdul HM, Opii W, Newman SF, Joshi G, Ansari MA, and Sultana R. Pin1 in Alzheimer's disease. J Neurochem 98: 1697-1706, 2006.
15. Butterfield DA, and Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703: 149-156, 2005.
16. Butterfield DA, Castegna A, Lauderback CM, and Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23: 655-664, 2002.
17. Butterfield DA, Drake J, Pocernich C, and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554, 2001.
18. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, and Bredesen DE. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48: 136-144, 2010.
19. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, and Martins RN. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 10: 391-397, 2006.
20. Butterfield DA, Howard B, Yatin S, Koppal T, Drake J, Hensley K, Aksenov M, Aksenova M, Subramaniam R, Varadarajan S, Harris-White ME, Pedigo NW, Jr., and Carney JM. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci 65: 1883-1892, 1999.
21. Butterfield DA, and Kanski J.Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23: 1299-1309, 2002.
22. Butterfield DA, and Lange ML. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem 111: 915-933, 2009.
23. Butterfield DA, and Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid betapeptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060, 2002.
24. Butterfield DA, Perluigi M, Reed T, Muharib T, Hughes CP, Robinson RA, and Sultana R. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal 17: 1610-1655, 2012.
25. Butterfield DA, Poon HF, Clair DS, Keller JN, Pierce WM, Klein JB, and Markesbery WR. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22: 223-232, 2006.
26. Butterfield DA, and Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12: 61-72, 2007.
27. Calabrese V, Cornelius C, Mancuso C, Lentile R, Stella AM, and Butterfield DA. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol 610: 285-308, 2010.
28. Calabrese V, Cornelius C, Rizzarelli E, Owen JB, Dinkova-Kostova AT, and Butterfield DA. Nitric oxide in cell survival: a janus molecule. Antioxid Redox Signal 11: 2717-2739, 2009.
29. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, and Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532, 2002.
30. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85: 1394-1401, 2003.
31. Cenini G, Dowling AL, Beckett TL, Barone E, Mancuso C, Murphy MP, Levine H, 3rd, Lott IT, Schmitt FA, Butterfield DA, and Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822: 130-138, 2012.
32. Cerpa WF, Barria MI, Chacon MA, Suazo M, Gonzalez M, Opazo C, Bush AI, and Inestrosa NC. The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2 + neurotoxicity in vivo. FASEB J 18: 1701-1703, 2004.
33. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, and Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60: 1374-1377, 2003.
34. Chetelat G, Eustache F, Viader F, De La Sayette V, Pelerin A, Mezenge F, Hannequin D, Dupuy B, Baron JC, and Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11: 14-25, 2005.
35. Ciccotosto GD, Tew D, Curtain CC, Smith D, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, and Barnham KJ. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 279: 42528-42534, 2004.
36. Clementi ME, Pezzotti M, Orsini F, Sampaolese B, Mezzogori D, Grassi C, Giardina B, and Misiti F. Alzheimer's amyloid beta-peptide (1-42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. Biochem Biophys Res Commun 342: 206-213, 2006.
37. Copani A, Koh JY, and Cotman CW. Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport 2: 763-765, 1991.
38. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, and Barnham KJ. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276: 20466-20473, 2001.
39. Dai XL, Sun YX, and Jiang ZF. Attenuated cytotoxicity but enhanced betafibril of a mutant amyloid beta-peptide with a methionine to cysteine substitution. FEBS Lett 581: 1269-1274, 2007.
40. Dalle-Donne I, Scaloni A, and Butterfield DA. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. Hoboken; NJ: John Wiley and Sons: 2006.
41. de Leon MJ, George AE, Ferris SH, Rosenbloom S, Christman DR, Gentes CI, Reisberg B, Kricheff II, and Wolf AP. Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNR Am J Neuroradiol 4: 553-556, 1983.
42. Ding QX, Markesbery WR, Cecarini V, and Keller JN. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31: 705-710, 2006.
43. Drake J, Link CD, and Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 24: 415-420, 2003.
44. Drayer BP, Heyman A, Wilkinson W, Barrett L, and Weinberg T. Early-onset Alzheimer's disease: an analysis of CT findings. Ann Neurol 17: 407-410, 1985.
45. Driver JA, and Lu KP. Pin1: a new genetic link between Alzheimer's disease, cancer and aging. Curr Aging Sci 3: 158-165, 2010.
46. Farrow TF, Thiyagesh SN, Wilkinson ID, Parks RW, Ingram L, and Woodruff PW. Fronto-temporal-lobe atrophy in early-stage Alzheimer's disease identified using an improved detection methodology. Psychiatry Res 155: 11-19, 2007.
47. Folstein MF, Folstein SE, and McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198, 1975.
48. Gabbita SP, Aksenov MY, Lovell MA, and Markesbery WR. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J Neurochem 73: 1660-1666, 1999.
49. Gabbita SP, Lovell MA, and Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034-2040, 1998.
50. Ganjei JK. Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond. Drug News Perspect 23: 573-584, 2010.
51. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, and Nicholson DW. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406, 1999.
52. Geula C, Mesulam MM, Saroff DM, and Wu CK. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J Neuropathol Exp Neurol 57: 63-75, 1998.
53. Glabe CC. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38: 167-177, 2005.
54. Goate A. Segregation of a missense mutation in the amyloid beta-protein precursor gene with familial Alzheimer's disease. J Alzheimers Dis 9: 341-347, 2006.
55. Goate A, and Hardy J. Twenty years of Alzheimer's diseasecausing mutations. J Neurochem 120 Suppl 1: 3-8, 2012.
56. Guidi I, Galimberti D, Lonati S, Novembrino C, Bamonti F, Tiriticco M, Fenoglio C, Venturelli E, Baron P, Bresolin N, and Scarpini E. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27: 262-269, 2006.
57. Guillozet AL, Weintraub S, Mash DC, and Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60: 729-736, 2003.
58. Gyure KA, Durham R, Stewart WF, Smialek JE, and Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489-492, 2001.
59. Halliwell B, and Gutteridge JM. Biologically relevant metal ion-dependent hydroxyl radical generation. An update. FEBS Lett 307: 108-112, 1992.
60. Hardy J, and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
61. Hattori T, Takei N, Mizuno Y, Kato K, and Kohsaka S. Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat-brain. Neurosci Res 21: 191-198, 1995.
62. Hebert LE, Scherr PA, Bienias JL, Bennett DA, and Evans DA. Alzheimer disease in the US population-prevalence estimates using the 2000 census. Arch Neurol 60: 1119-1122, 2003.
63. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, and Butterfield DA. Brain regional correspondence between Alzheimers-disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146-2156, 1995.
64. Hensley K, Maidt ML, Yu ZQ, Sang H, Markesbery WR, and Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates regionspecific accumulation. J Neurosci 18: 8126-8132, 1998.
65. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, and Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17: 302-316, 2002.
66. Hoogland C, Mostaguir K, Sanchez JC, Hochstrasser DF, and Appel RD. SWISS-2DPAGE, ten years later. Proteomics 4: 2352-2356, 2004.
67. Hoogland C, Sanchez JC, Tonella L, Binz PA, Bairoch A, Hochstrasser DF, and Appel RD. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res 28: 286-288, 2000.
68. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, and Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616, 1999.
69. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, and Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908-22914, 1996.
70. Jack CR, Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, and Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52: 1397-1403, 1999.
71. Jarrett JT, Berger EP, and Lansbury PT, Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697, 1993.
72. Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, Carmona-Cuenca I, Caballero C, Ruano D, Gutierrez A, and Vitorica J. Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 286: 18414-18425, 2011.
73. Jin M, Shepardson N, Yang T, Chen G, Walsh D, and Selkoe DJ. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108: 5819-5824, 2011.
74. Johansson AS, Bergquist J, Volbracht C, Paivio A, Leist M, Lannfelt L, and Westlind-Danielsson A. Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport 18: 559-563, 2007.
75. Jomova K, Vondrakova D, Lawson M, and Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345: 91-104, 2010.
76. Joshi YB, and Pratico D. Vitamin E in aging, dementia, and Alzheimer's disease. Biofactors 38: 90-97, 2012.
77. Jovanovic SV, Clements D, and MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med 25: 1044-1048, 1998.
78. Kanski J, Aksenova M, and Butterfield DA. The hydrophobic environment of Met35 of Alzheimer's Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotox Res 4: 219-223, 2002.
79. Kanski J, Aksenova M, Schoneich C, and Butterfield DA. Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. Free Radic Biol Med 32: 1205-1211, 2002.
80. Katzman R, and Saitoh T. Advances in Alzheimer's disease. FASEB J 5: 278-286, 1991.
81. Keeney JT, Swomley AM, Harris JL, Fiorini A, Mitov MI, PerluigiM, Sultana R, and ButterfieldDA. Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. Neurotox Res 22: 220-230, 2012.
82. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, and Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156, 2005.
83. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, andButterfieldDA. Peroxynitrite-inducedalterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 72: 310-317, 1999.
84. Landrieu I, Smet-Nocca C, Amniai L, Louis JV, Wieruszeski JM, Goris J, Janssens V, and Lippens G. Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS One 6: e21521, 2011.
85. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, and Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of A beta 1-42. J Neurochem 78: 413-416, 2001.
86. Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, Sun A, Finn G, Pastorino L, Lee VM, and Lu KP. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest 118: 1877-1889, 2008.
87. Lovell MA, Ehmann WD, Mattson MP, and Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-461, 1997.
88. LovellMA, and Markesbery WR. Oxidativelymodified RNA in mild cognitive impairment. Neurobiol Dis 29: 169-175, 2008.
89. Lu PJ, Wulf G, Zhou XZ, Davies P, and Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399: 784-788, 1999.
90. Luo S, and Levine RL. Methionine in proteins defends against oxidative stress. FASEB J 23: 464-472, 2009.
91. Ma SL, Pastorino L, Zhou XZ, and Lu KP. Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease. J Biol Chem 287: 6969-6973, 2012.
92. Mark RJ, Lovell MA, Markesbery WR, Uchida K, and Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid betapeptide. J Neurochem 68: 255-264, 1997.
93. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23: 134-147, 1997.
94. Markesbery WR, and Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 9: 133-146, 1999.
95. Markesbery WR, Kryscio RJ, Lovell MA, and Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58: 730-735, 2005.
96. Markesbery WR, and Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36, 1998.
97. Mary J, Vougier S, Picot CR, Perichon M, Petropoulos I, and Friguet B. Enzymatic reactions involved in the repair of oxidized proteins. Exp Gerontol 39: 1117-1123, 2004.
98. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245-4249, 1985.
99. Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils M, Waldemar G, Soininen H, and Lotjonen J. A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis 27: 163-176, 2011.
100. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081-1132, 1997.
101. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, and Mehta PD. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46: 412-416, 1999.
102. McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, and Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM-Monthly J Associaf Phys 94: 485-490, 2001.
103. Mecocci P, MacGarvey U, and Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751, 1994.
104. Migliore L, Fontana I, Trippi F, Colognato R, Coppede F, Tognoni G, Nucciarone B, and Siciliano G. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging 26: 567-573, 2005.
105. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, and Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301: 41-52, 1993.
106. Misiti F, Clementi ME, and Giardina B. Oxidation of methionine 35 reduces toxicity of the amyloid beta-peptide(1-42) in neuroblastoma cells (IMR-32) via enzyme methionine sulfoxide reductase A expression and function. Neurochem Int 56: 597-602, 2010.
107. Mohmmad Abdul H, Sultana R, Keller JN, St Clair DK, Markesbery WR, and Butterfield DA. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem 96: 1322-1335, 2006.
108. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, and Lemere CA. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9: 88-102, 2002.
109. Munch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, and Riederer P. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105: 439-461, 1998.
110. Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, and Bowers MT. Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J Am Chem Soc 131: 6316-6317, 2009.
111. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91: 8378-8382, 1994.
112. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, and Beach TG. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71: 362-381, 2012.
113. Nikolaev A, McLaughlin T, O'Leary DD, and Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981-989, 2009.
114. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767, 2001.
115. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, and Smith MA. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19: 1959-1964, 1999.
116. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holzman TF, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 136: 22-31, 1995.
117. Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, and Bush AI. Radioiodinated clioquinol as a biomarker for betaamyloid: Zn complexes in Alzheimer's disease. Aging Cell 5: 69-79, 2006.
118. Park SA, Shaked GM, Bredesen DE, and Koo EH. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. Biochem Biophys Res Commun 388: 450-455, 2009.
119. Perluigi M, and Butterfield DA. The identification of protein biomarkers for oxidative stress in Down syndrome. Expert Rev Proteomics 8: 427-429, 2011.
120. Perluigi M, and Butterfield DA. Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia. Curr Gerontol Geriatr Res 2012: 724904, 2012.
121. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, and Butterfield DA. Redox proteomics identification of 4-hydroxynonenal- modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3: 682-693, 2009.
122. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15: 93-101, 2000.
123. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194, 2004.
124. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, and Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66: 632-637, 2009.
125. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, and Cotman CW. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265, 1995.
126. Pogocki D, and Schoneich C. Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study. Chem Res Toxicol 15: 408-418, 2002.
127. Ranganathan R, Lu KP, Hunter T, and Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89: 875-886, 1997.
128. ReedT, PerluigiM, SultanaR, PierceWM,Klein JB, TurnerDM, Coccia R, Markesbery WR, and Butterfield DA. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30: 107-120, 2008.
129. Reed TT, Pierce WM, Jr., Turner DM, Markesbery WR, and Butterfield DA. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 13: 2019-2029, 2009.
130. Reed TT, Pierce WM, Markesbery WR, and Butterfield DA. Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274: 66-76, 2009.
131. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, and Masters CL. Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691, 2003.
132. Robinson RA, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, PierceWM, Bredesen DE, and Butterfield DA. Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: effects of the amyloid-beta peptide of amyloid precursor protein. Neuroscience 177: 207-222, 2011.
133. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870, 1996.
134. Schmidt M, Sachse C, Richter W, Xu C, Fandrich M, and Grigorieff N. Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci U S A 106: 19813-19818, 2009.
135. Schoneich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease. Biochim Biophys Acta 1703: 111-119, 2005.
136. Schoneich C, Pogocki D, Hug GL, and Bobrowski K. Free radical reactions of methionine in peptides: mechanisms relevant to beta-amyloid oxidation and Alzheimer's disease. J Am Chem Soc 125: 13700-13713, 2003.
137. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
138. Shan X, and Lin CLG. Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 27: 657-662, 2006.
139. Shan X, Tashiro H, and Lin CLG. The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 23: 4913-4921, 2003.
140. Small BJ, Fratiglioni L, and Backman L. Canaries in a coal mine: cognitive markers of preclinical Alzheimer disease. Arch Gen Psychiatry 58: 859-860, 2001.
141. Smith DG, Cappai R, and Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 1768: 1976-1990, 2007.
142. Smith MA, Harris PLR, Sayre LM, Beckman JS, and Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657, 1997.
143. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, and Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011.
144. Stadtman ER. Cyclic oxidation and reduction of methionine residues of proteins in antioxidant defense and cellular regulation. Arch Biochem Biophys 423: 2-5, 2004.
145. Stadtman ER, Moskovitz J, and Levine RL. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal 5: 577-582, 2003.
146. Subramanian A, and Miller DM. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275: 5958-5965, 2000.
147. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, and Butterfield DA. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging 27: 918-925, 2006.
148. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, and Butterfield DA. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27: 1564-1576, 2006.
149. Sultana R, and Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 19: 341-353, 2010.
150. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, and Butterfield DA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 24: 77-84, 2011.
151. Sultana R, Perluigi M, and Butterfield DA. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 833: 3-11, 2006.
152. Sultana R, Piroddi M, Galli F, and Butterfield D. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33: 2540-2546, 2008.
153. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, and Butterfield DA. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22: 76-87, 2006.
154. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, and Butterfield DA. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 11: 839-851, 2007.
155. Sultana R, Robinson RA, Bader LangeM, Fiorini A, Galvan V, Fombonne J, Baker A, Gorostiza O, Zhang J, Cai J, Pierce WM, Bredesen DE, and Butterfield DA. Do proteomics analyses provide insights into reduced oxidative stress in the brain of an Alzheimer disease transgenic mouse model with an M.631L amyloid precursor protein substitution and thereby the importance of amyloid-beta-resident methionine 35 in Alzheimer disease pathogenesis? Antioxid Redox Signal 17: 1507-1514, 2012.
156. Takei N, Kondo J, Nagaike K, Ohsawa K, Kato K, and Kohsaka S. Neuronal survival factor from bovine brain is identical to neuron-specific enolase. J Neurochem 57: 1178-1184, 1991.
157. Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, and Calon F. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 12: 377-390, 2007.
158. Varadarajan S, Kanski J, Aksenova M, Lauderback C, and Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J Am Chem Soc 123: 5625-5631, 2001.
159. Varadarajan S, Yatin S, Aksenova M, and Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130: 184-208, 2000.
160. Varadarajan S, Yatin S, Kanski J, Jahanshahi F, and Butterfield DA. Methionine residue 35 is important in amyloid beta-peptide-associated free radical oxidative stress. Brain Res Bull 50: 133-141, 1999.
161. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741, 1999.
162. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, and Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 61: 1965-1968, 1993.
163. Viola KL, Velasco PT, and Klein WL. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs). J Nutr Health Aging 12: 51S-57S, 2008.
164. Vlassenko AG, Benzinger TL, and Morris JC. PET amyloidbeta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta 1822: 370-379, 2012.
165. Waldemar G, Phung KT, Burns A, Georges J, Hansen FR, Iliffe S, Marking C, Rikkert MO, Selmes J, Stoppe G, and Sartorius N. Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 22: 47-54, 2007.
166. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, and Selkoe DJ. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30: 552-557, 2002.
167. Walsh DM, and Teplow DB. Alzheimer's disease and the amyloid beta-protein. ProgMol Biol Transl Sci 107: 101-124, 2012.
168. Wan L, Nie G, Zhang J, Luo Y, Zhang P, Zhang Z, and Zhao B. beta-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med 50: 122-129, 2010.
169. Wang J, Markesbery WR, and Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96: 825-832, 2006.
170. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, and Masters CL. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281: 17670-17680, 2006.
171. Yao Y, Clark CM, Trojanowski JQ, Lee VM, and Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58: 623-626, 2005.
172. Yatin SM, Varadarajan S, and Butterfield DA. Vitamin E prevents Alzheimer's amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2: 123-131, 2000.
173. Yatin SM, Varadarajan S, Link CD, and Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 20: 325-330; discussion 339-342, 1999.
174. Zheng H, and Koo EH. The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1: 5, 2006.